In vivo assays corroborated this combined therapy effectiveness and demonstrated that CEA is an excellent tumor-specific promoter for targeting therapeutic genes expression within lung cancer cells inducing apoptosis and with no harm to normal cells (13). The gene discussed is CEACAM5; the disease is lung carcinoma.